

4.0.3 DOC Cmte minutes

Macular Degeneration Guideline Committee – development

Date: 14/10/2015

Location: NICE offices, Manchester

NICE National Institute for
Health and Care Excellence

Minutes: Final

Committee members present:

| | |
|-------------------------|---------------------------------|
| Waqaar Shah (Chair) | Present for all items |
| Mary-Ann Sherratt (MAS) | Present for all items |
| Jennifer Evans (JE) | Present for all items |
| Elizabeth Wick (EW) | Present for all items |
| Cathie Burke (CB) | Present for items 1 to 7 (RQ8) |
| Carol McCletchie (CM) | Present for all items |
| Alexander Foss (AF) | Present for all items |
| Katy Barnard (KB) | Present for all items |
| Ellen Rule (ER) | Present for items 3 to 7 (RQ12) |
| Andy Charley (AC) | Present for all items |
| Mary Freeman (MF) | Present for all items |

In attendance:

| | | |
|-----------------------|--|-----------------------|
| Caroline Keir (CK) | NICE – Guideline Commissioning Manager | Present for all items |
| Stephen Duffield (SD) | ICG – Technical Analyst | Present for all items |
| Holly Irwin (HI) | ICG – Project Manager | Present for all items |
| Gabriel Rogers (GR) | ICG – Technical Advisor (HE) | Present for all items |

4.0.3 DOC Cmte minutes

| | | |
|----------------------|--------------------------------|--------------------------------|
| Andrea Heath (AH) | ICG – Information Specialist | Present for all items |
| Louisa Crossley (LC) | NICE – Medicine Senior Advisor | Present for items 1 to 7 (RQ6) |

Observers:

| | |
|--------------------|--|
| Judith Hughes (JH) | PhD student (present for items 1 to 7 RQ6) |
| Dave Nicholls (DN) | NICE Information Specialist |

Apologies:

| | |
|------------------------|--|
| Cathy Yelf (CY) | Committee member |
| Sarah Stephenson (SSt) | NICE – Guideline Commissioning Manager |

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the second meeting on age-related macular degeneration. The Committee members and attendees introduced themselves.

Apologies for the meeting were received as detailed above.

The Chair outlined the proposed objectives of the meeting, which included:

- Introduction to information searching
- Information about types of evidence
- Discussion regarding priorities for health economic modelling
- Agreement on review protocols

The Chair highlighted the importance of declaring conflicts of interest. He asked each attendee to declare any new conflicts since the previous meeting. No conflicts were declared with the following exceptions:

| Attendee | Declaration | Action |
|-------------------|--|-----------------------|
| Mary Freeman | Delegate at a seminar sponsored by MSD | Declare & participate |
| Mary-Ann Sherratt | Delegate at a seminar sponsored by Bayer | Declare & participate |
| Ellen Rule | Executive sponsor of a project funded by Bayer, undertaking health economic modelling on atrial fibrillation | Declare & participate |

4.0.3 DOC Cmte minutes

| | | |
|---------------|--|---|
| Judith Hughes | Owens small number of shares in Pfizer, following previous employment (over 8 years ago) | Declare & participate (acceptable in context of role as potential researcher) |
|---------------|--|---|

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

The Chair asked the committee for any comments regarding accuracy of the minute of the last meeting. AF highlighted an amendment, for accuracy, relating to the wording of a previously declared potential conflict of interest. Other than the amendment to declarations of interest, the minutes were agreed as an accurate record.

Action: HI to amend the draft minute of the previous meeting to reflect that AF had submitted a paper for publication.

The Chair advised the committee that Usha Chakravarthy has resigned from the committee due to unforeseen personal circumstances. The Chair reflected that her expertise would be missed within the committee. It was agreed that action to seek a replacement Ophthalmologist would take place.

2. Developing Clinical Guidelines – research student

The Chair introduced JH to the committee, as a PhD student wishing to access the committee in order to study the psycho/social aspects of guideline development. JH tabled a paper providing further background and detail relating to her area of research. JH explained that she was seeking consent from the committee to observe future meetings and interview a number of committee members to inform her research. The

4.0.3 DOC Cmte minutes

committee present were supportive of JH's proposal.

The Chair thanked JH for her input and confirmed that committee members would have the opportunity to feedback to HI if they had any concerns about being involved in the research, after receiving the draft minute of the meeting.

Action: committee to inform HI if they have any concerns about JH observing future meetings to inform her research.

3. Information searches

The Chair introduced AH who delivered a presentation on broad approaches to literature searching and a search strategy for macular degeneration. The committee were given the opportunity to ask questions. The Chair thanked AH for her presentation.

4. Types of evidence

The Chair introduced SD who presented an overview of different types of evidence, in the context of NICE methodology and the way that available evidence will be assessed by the technical team. The committee were able to ask questions about how this would relate to guideline development. The Chair thanked SD for his presentation.

5. Health economic prioritisation

The Chair introduced CG who delivered a follow up presentation on health economics, with a focus on seeking early feedback from the committee on areas of interest for original economic modelling. The committee discussed potential areas of interest for economic modelling and the various advantages and challenges involved in this. It was confirmed that this discussion would continue at the next meeting.

The Chair thanked CG for his presentation.

6. Review question 2 - update

The Chair introduced SD, who provided an update on progress since the last meeting in searching for and analysing evidence in relation to RQ2. SD highlighted some areas for discussion and clarification with the committee. Following discussion there was agreement on the approach to follow in progressing the review question.

7. Review protocol development

SD briefly introduced the committee to the process of review protocol development.

The committee considered and agreed the following review protocols with special focus on population, intervention, comparators and outcomes.

RQ12 – ‘What is the effectiveness of different anti-angiogenic therapies (including photodynamic therapy) for the treatment of neovascular AMD?’

RQ18: - ‘What is the effectiveness of different frequencies of administration of antiangiogenic therapies for the treatment of neovascular AMD?’

RQ7: - ‘What is the effectiveness of strategies to reduce the risk of developing AMD in the unaffected eye or slow the progression of AMD?’

It was noted that the review questions above are expected to be undertaken by Cochrane, in line with NICE methodology.

RQ6: - ‘What effective classification tool should be used to inform people with AMD?’

RQ1: - ‘What signs and symptoms should prompt a healthcare professional to suspect AMD in people presenting to healthcare services?’

RQ8: - ‘What is the effectiveness of psychological therapies for AMD?’

4.0.3 DOC Cmte minutes

RQ4: - 'What tools are useful for triage, diagnosis, informing treatment and determining management in people with suspected AMD?'

8. Next steps

The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed.

Date of next meeting: Wednesday 25th November

Location of next meeting: NICE offices, Manchester